There are no Transcripts on GBS.
Aug. 20, 2009, 11:56 AMFDA says Merck's (MRK -0.9%) vaccine to prevent cervical cancer, Gardasil, "continues to be safe and effective, and its benefits continue to outweigh its risks." Noting concerns over adverse effects, including death and Guillain-Barre Syndrome (GBS), FDA says none of the adverse events were at rates greater than expected. (FDA) | Comment!
There are no StockTalks on this stock yet.
Currently, there's no company description for GBS.
Country: United States
Other News & PR